Citius Pharmaceuticals (CTXR) Earnings Date, Estimates & Call Transcripts $1.17 +0.03 (+2.63%) Closing price 04:00 PM EasternExtended Trading$1.18 +0.02 (+1.28%) As of 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Citius Pharmaceuticals Earnings Summary Citius Pharmaceuticals issued Q3 2025 earnings on August 12, 2025, reporting an EPS of -$0.80, which missed the consensus estimate of -$0.76 by $0.04. Quarterly revenue was reported to be $1.92 million, above the consensus estimate of $1.92 million. With a trailing EPS of $0.00, Citius Pharmaceuticals' earnings are expected to grow next year, from ($4.50) to $1.25 per share. Latest Q3 Earnings DateAug. 12EstimatedConsensus EPS (Aug. 12) -$0.76 Actual EPS (Aug. 12) -$0.80 Missed By -$0.04 Actual Revenue (Aug. 12) $1.92MQ3 2025 Earnings ResourcesQ3 2025 Earnings Report Quarterly Report (10-Q) Press Release (8-K)Powered by Get Citius Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Citius Pharmaceuticals and other key companies, straight to your inbox. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Estimated and Actual Earnings DataCTXR Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Citius Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.05-$0.05-$0.05Q2 20251-$0.05-$0.05-$0.05Q3 20251-$0.04-$0.04-$0.04Q4 20251-$0.04-$0.04-$0.04 Citius Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails8/12/2025Q3 2025-$0.76-$0.80 -$0.04-$0.80$1.92M$1.92M5/14/2025Q2 2025-$1.08-$1.27 -$0.19-$1.27--2/14/2025Q1 2025-$1.25-$1.30 -$0.05-$1.30--8/12/2024--$1.25-$1.50 -$0.25-$0.06--5/14/2024Q2 2024-$1.50-$1.25+$0.25-$0.05--2/14/2024Q1 2024$3.25-$1.50 -$4.75-$0.06--12/29/2023Q4 2023-$0.50-$1.75 -$1.25-$0.07-- Citius Pharmaceuticals Earnings - Frequently Asked Questions When did Citius Pharmaceuticals announce their last quarterly earnings? Citius Pharmaceuticals (NASDAQ:CTXR) last announced its quarterly earning data on Tuesday, August 12, 2025. Learn more on CTXR's earnings history. Did Citius Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Citius Pharmaceuticals (NASDAQ:CTXR) missed the analysts' consensus estimate of ($0.76) by $0.04 with a reported earnings per share (EPS) of ($0.80). Learn more on analysts' earnings estimate vs. CTXR's actual earnings. How much profit does Citius Pharmaceuticals generate each year? Citius Pharmaceuticals (NASDAQ:CTXR) has a recorded net income of -$39.14 million. CTXR has generated $0.00 earnings per share over the last four quarters. What is Citius Pharmaceuticals' EPS forecast for next year? Citius Pharmaceuticals' earnings are expected to grow from ($4.50) per share to $1.25 per share in the next year. More Earnings Resources from MarketBeat Related Companies Elutia Earnings Sol-Gel Technologies Earnings PMV Pharmaceuticals Earnings Unicycive Therapeutics Earnings Assertio Earnings IGM Biosciences Earnings Opus Genetics Earnings Immunic Earnings BeyondSpring Earnings Shattuck Labs Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Wall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a Winner This page (NASDAQ:CTXR) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersFanatics Hit $31B-Is This Nasdaq Next?Fanatics built an empire by owning the fan experience-scaling to a $31B valuation. But the next wave isn't abo...i2i Marketing Group, LLC | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredFree: The Crypto Summit That Could Change Your LifeWall Street’s Crypto Playbook—Revealed at This Free Event If you want to understand what's really happening...Crypto 101 Media | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
